Go Pro
OTCMKTS:EVTCY

Evotec (EVTCY) Stock Price, News & Analysis

Evotec logo
$1.63 -0.05 (-2.98%)
As of 09/15/2026

About Evotec Stock (OTCMKTS:EVTCY)

Advanced

Key Stats

Today's Range
$1.60
$1.65
50-Day Range
$1.68
$2.85
52-Week Range
$14.22
$26.57
Volume
102,165 shs
Average Volume
2,407 shs
Market Capitalization
$538.26 million
P/E Ratio
3.98
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evotec SE is a Germany-based drug discovery and development company that partners with pharmaceutical, biotechnology and academic organizations. The company provides integrated research services and technology platforms designed to support the development of new medicines, from early-stage target identification and screening through preclinical research and selected clinical development activities.

Evotec’s capabilities include small-molecule drug discovery, biologics research, cell and gene-related technologies, disease modeling, compound screening and data-driven drug development. Its scientific platforms include induced pluripotent stem cell research and targeted protein degradation, while its work spans therapeutic areas such as neuroscience, oncology, immunology, metabolic disease and infectious disease. Evotec also develops proprietary and partnered drug candidates, which may be advanced through collaborations with pharmaceutical companies and other research organizations.

Founded in Hamburg in 1993 as Evotec BioSystems, the company has expanded its operations across Europe and the United States. Its activities are conducted through research and development sites in several locations, including Germany, the United Kingdom, France, Italy and the United States. Evotec is headquartered in Hamburg and is led by Chief Executive Officer Christian Wojczewski.

AI Generated. May Contain Errors.

Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EVTCY Stock News Headlines

Evotec SE ADR (EVTCY)
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40 trillion by fall. Servicing that debt now costs more than the entire defense budget, while inflation above 3.5% keeps eroding cash savings. Central banks are responding by buying gold at the fastest pace in decades. The U.S. Gold Bureau's complimentary guide covers IRA-eligible gold and silver options, secure storage, and a fast BuyBack Guarantee.tc pixel
See More Headlines

EVTCY Stock Analysis - Frequently Asked Questions

Evotec's stock was trading at $3.08 on January 1st, 2026. Since then, EVTCY shares have decreased by 47.1% and is now trading at $1.63.

Evotec's stock split before market open on Wednesday, October 20th 2021.The 3-1 split was announced on Wednesday, October 20th 2021. The newly issued shares were issued to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Evotec subsidiaries include these companies: Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and others.

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
9/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
OTCMKTS:EVTCY
CIK
1412558
Employees
4,200
Year Founded
1993

Profitability

EPS (Trailing Twelve Months)
$0.41
Trailing P/E Ratio
3.98
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$7.14 million
Net Margins
20.85%
Pretax Margin
23.90%
Return on Equity
16.02%
Return on Assets
7.81%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
2.57
Quick Ratio
2.50

Sales & Book Value

Annual Sales
$572.16 million
Price / Sales
0.94
Cash Flow
$0.02 per share
Price / Cash Flow
105.53
Book Value
$2.52 per share
Price / Book
0.65

Miscellaneous

Outstanding Shares
330,221,000
Free Float
N/A
Market Cap
$538.26 million
Optionable
Not Optionable
Beta
0.98

Social Links

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:EVTCY) was last updated on 9/16/2026 by MarketBeat.com Staff.
From Our Partners